Form 4: Lucid Diagnostics CFO Dennis McGrath Receives 400,000 Shares of Restricted Stock

Lucid Diagnostics' Chief Financial Officer, Dennis M. McGrath, acquired 400,000 shares of restricted stock on May 7, 2024, under the company's 2018 Equity Plan.

Summary

• On May 7, 2024, Dennis M. McGrath, the Chief Financial Officer of Lucid Diagnostics Inc., acquired 400,000 shares of common stock.
• These shares were granted as restricted stock under the Issuer's 2018 Equity Plan.
• The restricted stock has a single vesting date of May 20, 2026, and is subject to forfeiture if the required service period is not completed.
• The reporting person's total holdings after the transaction amount to 1,043,569 shares.
• This includes 19,169 shares of Lucid common stock distributed by PAVmed on February 15, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of restricted stock is a common practice and aligns the CFO's interests with the company's long-term performance. There are no immediate negative implications.

Positives

• The grant of restricted stock to the CFO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the CFO.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could be a risk if the CFO were to leave the company before the vesting date.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders by aligning the CFO's interests with the company's long-term success.
• Employees may view the grant of restricted stock as a positive sign of the company's commitment to its executives.

Key Dates